In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
484 News Items found
Updates from SABCS 2021: Personalizing Diet and Exercise Plans for Breast Cancer, Zapping Metastatic Cells, Making Targeted Drugs Work Better

MSK physicians and researchers discussed the latest trends in breast cancer research at the annual meeting held in San Antonio.
In the Clinic
Head shot of doctor with glasses, white shirt, and blue tie in his lab.
Drug Reduces Recurrence Risk in Subset of Women with Breast Cancer

A drug was shown to improve outcomes in women with HER2-positive early breast cancer when added to standard therapy.
In the Clinic
Shanu Modi
FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer: Trastuzumab Deruxtecan (T-DXd)

On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.
Reilly Starr with her husband and their son on her husband's shoulders
Always by Your Side: How MSK Helps People Facing Metastatic Breast Cancer

Learn how people facing metastatic breast cancer help each other in support groups at Memorial Sloan Kettering.
In the Clinic
Medical oncologist Mark Robson
Phase III Trial of Targeted Drug Shows Promise in Treating Metastatic Breast Cancer

Investigators found that olaparib extended progression-free survival by an average of three months in women with advanced breast cancer.
In the Clinic
MSK radiation oncologist Beryl McCormick confers with a patient
Will Radiation Therapy Protect Me from Breast Cancer Recurrence after Surgery? What to Know

Learn about the role of radiation therapy in protecting women from breast cancer recurrence after breast-conserving surgery.
Article
Woman smiling with Central Park in the background.
New Drug Combination Improves Survival for ER+, HER2- Breast Cancer

Learn about a three-drug treatment that has been shown to extend survival for ER+, HER2- breast cancers.
In the Clinic
Andrea Barrio (right) and fellow Shirin Muhsen focus on surgery for breast cancer.
Sessions at Annual Breast Cancer Conference Focus on Prevention and Treatment of Lymphedema

Experts from Memorial Sloan Kettering presented some of the latest research on this challenging complication of many cancer surgeries.
Memorial Sloan Kettering Breast Cancer Experts to Gather at Annual San Antonio Breast Cancer Symposium

Experts from all specialties of breast cancer treatment will attend the 2018 San Antonio Breast Cancer Symposium from December 4 through 8. It is the largest annual meeting devoted solely to the latest in breast cancer advances. The meeting will highlight emerging research and also tackle some of the larger issues facing people with breast cancer and the doctors who treat them.
Q&A
Illustration of immune cell opening as if on hinge and boxing glove coming out.
New Approach Could Boost Immunotherapy for Breast Cancer

A protein on certain immune cells is a promising target for making immunotherapy more effective against breast cancer.